13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q4 2023 · Filed November 14, 2023 · Accession 0000950123-23-010476
Total Value
$108.9M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Replimune Group | REPL | 3,001,319 | $51.4M | 47.17% |
| 2 | Nuvation Bio | NUVB | 15,072,340 | $20.2M | 18.55% |
| 3 | Ikena Oncology | 45175G108 | 2,249,123 | $9.7M | 8.94% |
| 4 | Morphic Holding | 61775R105 | 309,846 | $7.1M | 6.52% |
| 5 | Kronos Bio | 50107A104 | 3,818,283 | $5.0M | 4.56% |
| 6 | Spruce Biosciences | SPRB | 2,161,022 | $4.9M | 4.49% |
| 7 | Sana Biotechnology, Inc. | SANA | 843,750 | $3.3M | 3.00% |
| 8 | Immunic Inc | IMUX | 1,788,160 | $2.6M | 2.41% |
| 9 | Theseus Pharmaceuticals | 88369M101 | 711,479 | $1.9M | 1.76% |
| 10 | Alpine Immune Sciences | 02083G100 | 153,700 | $1.8M | 1.62% |
| 11 | Syros Pharmaceuticals | 87184Q206 | 251,270 | $992,517 | 0.91% |
| 12 | Senti Biosciences, Inc. | SNTI | 195,792 | $80,862 | 0.07% |